|
Match
|
Document |
Document Title |
|
|
7618985 |
Isoquinoline derivatives
The invention relates to isoquinoline derivatives having the general Formula I
wherein X is O, S or NH; Y is OH or NH 2 ; m is 0, 1 or 2; n is 1 or 2; R 1 is H, when Y is NH 2 ; or R 1 is H,...
|
|
|
7618984 |
Sulfonamide compound
A compound represented by the formula (1) [A represents a nitrogen-containing saturated ring; m represents an integer of 0 to 2; n represents an integer of 1 to 4; G 1 represents hydrogen atom,...
|
|
|
7615565 |
VEGFR-2 and VEGFR-3 inhibitory anthranilamide pyridines
VEGFR-2 and VEGFR-3 inhibitory anthranilamide pyridinamides, their production and use as pharmaceutical agents for treating diseases that are triggered by persistent angiogenesis, as well as...
|
|
|
7612091 |
Caspase inhibitors and uses thereof
The present invention provides a compound of formula I:
wherein:
X is —OR 1 or —N(R 5 ) 2 , Y is halo, trifluorophenoxy, or tetrafluorophenoxy; R 1 is:
C 1-6 straight...
|
|
|
7582638 |
Pyrazole-isoquinoline urea derivatives as p38 kinase inhibitors
The present invention provides kinase inhibitors of Formula (I) wherein R1, R2, and X are as described herein, or a pharmaceutically acceptable salt thereof.
|
|
|
7572913 |
4-substituted piperidine derivatives
Substituted piperidine compounds represented by the structure I are provided,
wherein each of R 1a , R 1b , R 1c , R 1d , R 1e , R 1f , R 1g , R 1h , R 2 , R 2A , R 3 , R 4 , A, X, a, x and n...
|
|
|
7572809 |
Isoquinoline aminopyrazole derivatives
The present invention relates to the compounds of formula I:
their pharmaceutically acceptable salts or esters, enantiomeric forms, diastereoisomers and racemates, the preparation of such...
|
|
|
7553852 |
Caspase inhibitors and uses thereof
The present invention relates to compounds of formula I:
useful as inhibitors of caspases. The present invention also provides pharmaceutically acceptable compositions comprising said...
|
|
|
7528133 |
Use of thiazolidinediones derivatives for preventing uterine contractions in premature labour or lactation
The present invention provides methods of preventing or reducing oxytocin-mediated action by using a thiazolidinedione, such as troglitazone, or thiazolidinedione-like compounds. These methods...
|
|
|
7511027 |
Method of treating hepatitis delta virus infection
A method for the treatment for hepatitis delta infection in a host, that includes administering an effective amount of a nucleoside or a nucleoside analog that suppresses the expression of the...
|
|
|
7501412 |
Isoquinoline compounds and medicinal use thereof
The present invention relates to an isoquinoline compound represented by the following formula (I) or (II), an optically active form thereof, a pharmaceutically acceptable salt thereof, a water...
|
|
|
7488737 |
Indoles, 1H-indazoles, 1,2-benzisoxazoles, 1,2-benzoisothiazoles, and preparation and uses thereof
The present invention relates generally to the field of ligands for nicotinic acetylcholine receptors (nACh receptors), activation of nACh receptors, and the treatment of disease conditions...
|
|
|
7482341 |
Pyridines
Compounds of formula
as well as pharmaceutically acceptable salts and esters thereof, wherein R 1 to R 6 have the significance given in claim 1 can be used in the form of pharmaceutical...
|
|
|
7456183 |
Guanidino compounds
Compounds having the general structure I are provided. X and Y are independently selected from the group consisting of CH 2 , N, NR 9 , C═O, C═S, S═O, SO 2 , S, O, (CR 6 R 7 ) n ,...
|
|
|
7442710 |
Substituted phenyl methanones
The present invention relates to compounds of general formula IA or IB
wherein
X 1 and X 2 are each independently N or C—R″ and R 1 , R 2 ,R 3 , R 4 , R 5 , and R 6 are as defined in...
|
|
|
7439242 |
PPARγ modulators
Modulators of PPARγ activity are provided which are useful in pharmaceutical compositions and methods for the treatment of conditions such as type II diabetes and obesity.
|
|
|
7407972 |
Inhibitors of factor Xa and other serine proteases involved in the coagulation cascade
The present invention provides compounds of Formula (I):
wherein A, B, C, G, and W 1 have any of the values defined in the specification, and pharmaceutically acceptable salt thereof, that are...
|
|
|
7405227 |
Treatment of cancer
Methods of treating ovarian cancer, endometrium cancer, cervical cancer, pancreatic cancer, bladder cancer, eve cancer, central nervous system cancer, thyroid cancer and lung cancer are disclosed....
|
|
|
7402673 |
Diamine β2 adrenergic receptor agonists
The invention provides novel β 2 adrenergic receptor agonist compounds. The invention also provides pharmaceutical compositions comprising such compounds, methods of using such compounds to treat...
|
|
|
7402595 |
JNK inhibitor
A JNK inhibitor containing a compound having an isoquinolinone skeleton or a salt thereof, such as a compound represented by the formula
wherein ring A and ring B are each an optionally...
|
|
|
7390820 |
Substituted quinolinone derivatives and methods of use
Selected compounds are effective for prophylaxis and treatment of diseases, such as angiogenesis mediated diseases. The invention encompasses novel compounds, analogs, prodrugs and pharmaceutically...
|
|
|
7390798 |
Carboxamide spirolactam CGRP receptor antagonists
The present invention is directed to compounds of Formula I: I (where variables A 1 , A 2 , B, J, K, m, n, R 4 , R 5a , R 5b and R 5c are as defined herein) useful as antagonists of CGRP...
|
|
|
7309708 |
Hepatitis C virus inhibitors
Hepatitis C virus inhibitors are disclosed having the general formula:
wherein R 1 , R 2 , R 3 , R′, B, Y and X are described in the description. Compositions comprising the compounds and...
|
|
|
7294635 |
Substituted isoquinolinones
Isoquinolinone compounds are provided that are useful for the inhibition of ADP-platelet aggregation, particularly in the treatment of thrombosis and thrombosis related conditions or disorders.
|
|
|
7265131 |
Isoquinolinone derivatives and their use as therapeutic agents
Compounds of formula (I):
wherein n, R 1 , R 2 , R 3 and R 7 are disclosed herein, are useful in treating disease-states associated with nuclear receptor activity. Pharmaceutical compositions...
|
|
|
7265130 |
NPY Y5 antagonist
The present invention provides a pharmaceutical composition for use as an NPY Y5 receptor antagonist comprising a compound of the formula (I):
wherein R 1 is lower alkyl, cycloalkyl or the...
|
|
|
7253160 |
Depeptidized inhibitors of hepatitis C virus NS3 protease
The present invention discloses novel depeptidized compounds which have HCV protease inhibitory activity as well as pharmaceutical compositions comprising such compounds and methods of using them...
|
|
|
7220759 |
Isoquinoline compound and pharmaceutical use thereof
The present invention relates to an isoquinoline compound represented by the following formula (I), an optically active form thereof, a pharmaceutically acceptable salt thereof, a water adduct...
|
|
|
7205315 |
Bicyclic imino acid derivatives as inhibitors of matrix metalloproteinases
The present invention is directed to a compound of formula (I), or a stereoisomer or a mixture of stereoisomer thereof in any ratio, or its physiologically tolerable salt, which is useful as an...
|
|
|
7196088 |
Substituted tetrahydroisoquinolines and uses thereof
The invention provides compounds of the formula:
and pharmaceutically acceptable salts or prodrugs thereof, wherein, n, X, Y, R 1 , R 2 , R 3 , R 4 and R 5 are as defined herein. The subject...
|
|
|
7173057 |
Ketoamides with cyclic P4'S as inhibitors of NS3 protease of hepatitis C virus
The present invention discloses novel compounds which have HCV protease inhibitory activity as well as methods for preparing such compounds. In another embodiment, the invention discloses...
|
|
|
7144894 |
Sulfonamide bicyclic compounds
The invention encompasses compounds of Formula I, including pharmaceutically acceptable salts and solvates, their pharmaceutical compositions, and their uses in inhibiting β-amyloid peptide...
|
|
|
7125863 |
Inhibitors of dipeptidyl peptidase IV
Compounds according to formula (1), wherein R 1 is H or CN, X 1 is S, O, SO 2 or CH 2 , X 2 is CO, CH 2 or a covalent bond, Het is a nitrogen-containing heterocycle and n is 1–5 are new. The...
|
|
|
7109212 |
Quinoline and isoquinoline derivatives, a process for their production and their use as inflammation inhibitors
The invention relates to quinoline and isoquinoline derivatives of general formula I
and a process for their production, and their use as inflammation inhibitors.
|
|
|
RE39265 |
Heteroarylpiperidines, and their use as antipsychotics and analgetics
Heteroarylpiperidines, pyrrolidines, and piperazines are useful as antipsychotic and analgesic agents. The compounds are especially useful for treating psychoses by administering to a mammal a...
|
|
|
7030136 |
Use of phanquinone for the treatment or prevention of memory impairment
The use of phanquinone (4,7-phenanthroline-5,6-dione) for the treatment or prevention of memory impairment is suggested. Also a method for improving the learning or memory of a normal subject is...
|
|
|
6998408 |
6-5, 6-6, or 6-7 Heterobicycles as factor Xa inhibitors
The present application describes 6–5, 6—6, or 6–7 heterobicycles of Formula I or pharmaceutically acceptable salt forms thereof:
wherein ring P is a 6-membered heteroaromatic and ring M...
|
|
|
6992084 |
Compounds and methods for modulating CXCR3 function
The invention provides compounds and compositions of the formula:
wherein,
the subscript n is an integer of from 0 to 4; Ar is a member selected from the group consisting of substituted...
|
|
|
6974822 |
3-isoquinolinone derivatives as matrix metalloproteinase inhibitors
This invention provides compounds defined by Formula I:
or a pharmaceutically acceptable salt thereof,
wherein R 1 , Q, R 2 , R 3 , R 4 , and n are as defined in the specification. The...
|
|
|
6964782 |
Stable hydrogen peroxide compositions, products and methods of use
Disclosed are several preferred embodiments of hydrogen peroxide which are packaged with ease of use and extended shelf-life in mind. The embodiments include foam, mist, gel, and disposable...
|
|
|
6962927 |
Method for potentiating primary drugs in treating multidrug resistant disease
The specification discloses a method for enhancing the inhibiting action of drugs against multidrug resistant cells, apparently by reversing or inhibiting the glycoprotein “pumps” associated...
|
|
|
6949567 |
Compounds for the treatment of protozoal diseases
The invention relates to new diphenylurea having the formula (I)
or a salt thereof, where
Y is C═O, C═S, C═NH, (C═O) 2 or SO 2 ; and to processes for the preparation of these...
|
|
|
6939867 |
β3 agonists and uses thereof
Sulfamide compounds having formula (I) are described as well as their use in the treatment of diseases dependent on the signaling pathways associated with β-adrenergic receptors, such as obesity,...
|
|
|
6906061 |
Pharmaceutical agent containing Rho kinase inhibitor
A Rho kinase inhibitor is provided as a novel pharmaceutical agent, particularly as a therapeutic agent of hypertension, a therapeutic agent of angina pectoris, a suppressive agent of...
|
|
|
6878706 |
Cyanamides useful as reversible inhibitors of cysteine proteases
Compounds according to the following formula (I):
wherein the variables Q and R 1 to R 6 are as described herein, which reversibly inhibit the cysteine proteases, such as cathepsins K, S, F,...
|
|
|
6875761 |
Certain 1,3-disubstituted isoquinoline derivatives
Condensed pyridine compounds represented by formula (I):
wherein: R 1 and R 3 are, independently, hydrogen, lower alkyl, or lower alkoxy; R 2 represent an amino substituent; ring A is a...
|
|
|
6855708 |
N-arylsulfonyl aza-bicyclic derivatives as potent cell adhesion inhibitors
Compounds of Formula I are antagonists of VLA-4 and/or alpha4/beta7, and as such are useful in the inhibition or prevention of cell adhesion and cell-adhesion mediated pathologies. These compounds...
|
|
|
6825213 |
β3-adrenoreceptor agonists, agonist compositions and methods of using
The invention provides β 3 -adrenoreceptor agonists, pharmaceutical compositions comprising β 3 -adrenoreceptor agonist compounds, and methods of using such compounds for stimulating, regulating...
|
|
|
6815440 |
Cyclic and heterocyclic N-substituted α-iminohydroxamic and -carboxylic acids
Cyclic and heterocyclic N-substituted α-iminohydroxamic and -carboxylic acids Compounds of the formula I are suitable for preparing pharmaceuticals for the treatment of disorders in the course...
|
|
|
6794412 |
Treatment of thrombosis by combined use of a factor Xa inhibitor and aspirin
Provided is a method of treating thrombosis in mammals by administering therapeutically effective amounts of a combination of (i) a Factor Xa inhibitor, and (ii) a compound selected from the group...
|